Probiotic therapeutics and microbiota research for digestive and immune health
Institut AllergoSan manufactures prescription and consumer probiotics grounded in 30+ years of microbiota research. The tech stack is purely Microsoft enterprise infrastructure (365, Azure, Teams, SharePoint) with Adobe creative tools—a profile typical of regulated pharma ops with minimal R&D software footprint, matching their project focus on clinical validation, physician education, and manufacturing scale rather than software-driven innovation. Sales hiring (15 roles) outpaces all other departments; current hiring velocity is minimal, suggesting market positioning is already established.
Institut AllergoSan, headquartered in Graz, Austria, researches and manufactures probiotics and microbiota-focused therapeutics. The company operates research teams across Europe, America, and Asia developing probiotic medications and nutritional supplements, with particular focus on indication-specific treatments for antibiotic-associated diarrhea, allergy, gut health, and metabolic disorders. Products meet pharmaceutical-grade quality standards and are sold through physician and pharmacy channels in German-speaking markets. The 201–500-person organization operates as a privately held, science-driven manufacturer with active pipelines in clinical training, conference participation, and regional market expansion.
The company uses Microsoft 365 suite (Exchange, Teams, SharePoint, OneDrive, Intune, Azure Entra ID, Windows), Adobe Creative Cloud (Premiere Pro, After Effects, DaVinci Resolve), and Google services. No enterprise R&D or biotech-specific software tools are currently in use.
The company has 201–500 employees. The organization is structured around sales-led go-to-market (15 sales roles), research operations, and manufacturing in Austria.
Other companies in the same industry, closest in size